Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC.

Literature DB >> 27275460

STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC.

Sarani Ghoshal¹, Bryan C Fuchs¹, Kenneth K Tanabe¹.

Abstract

Cancer stem cell (CSC) marker CD133 was found to be upregulated in many cancers including hepatocellular carcinoma (HCC). However, the molecular mechanism of CD133 regulation in the liver tumor microenvironment has remained elusive. In this study Won and colleagues report that interleukin-6 (IL-6) mediated signal transducer and activator of transcription factor 3 (STAT3) signaling and hypoxia enhance the expression of CD133 and promote the progression of HCC.

Entities: Disease Gene

Keywords: CD133; hepatocellular carcinoma (HCC); interleukin-6 (IL-6); signal transducer and activator of transcription factor 3 (STAT3)

Year: 2016 PMID： 27275460 PMCID： PMC4876240 DOI： 10.21037/hbsn.2016.03.02

Source DB: PubMed Journal: Hepatobiliary Surg Nutr ISSN： 2304-3881 Impact factor: 7.293

8 in total

1. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity.

Authors: Shengyong Yin; Jinjun Li; Chen Hu; Xinhua Chen; Ming Yao; Mingxia Yan; Guoping Jiang; Chao Ge; Haiyang Xie; Dafang Wan; Shengli Yang; Shusen Zheng; Jianren Gu
Journal: Int J Cancer Date: 2007-04-01 Impact factor: 7.396

2. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.

Authors: Shanshan Wan; Ende Zhao; Ilona Kryczek; Linda Vatan; Anna Sadovskaya; Gregory Ludema; Diane M Simeone; Weiping Zou; Theodore H Welling
Journal: Gastroenterology Date: 2014-08-30 Impact factor: 22.682

3. A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis.

Authors: Taranjit S Gujral; Marina Chan; Leonid Peshkin; Peter K Sorger; Marc W Kirschner; Gavin MacBeath
Journal: Cell Date: 2014-11-06 Impact factor: 41.582

4. Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis.

Authors: Reiner Wiest; Johanna Weigert; Josef Wanninger; Markus Neumeier; Sabrina Bauer; Sandra Schmidhofer; Stefan Farkas; Marcus N Scherer; Andreas Schäffler; Jürgen Schölmerich; Christa Buechler
Journal: Cytokine Date: 2010-07-15 Impact factor: 3.861

5. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.

Authors: S Ma; T K Lee; B-J Zheng; K W Chan; X-Y Guan
Journal: Oncogene Date: 2007-09-24 Impact factor: 9.867

Review 6. Cancer stem cells in the development of liver cancer.

Authors: Taro Yamashita; Xin Wei Wang
Journal: J Clin Invest Date: 2013-05-01 Impact factor: 14.808

Review 7. Cancer stem cells: impact, heterogeneity, and uncertainty.

Authors: Jeffrey A Magee; Elena Piskounova; Sean J Morrison
Journal: Cancer Cell Date: 2012-03-20 Impact factor: 31.743

8. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma.

Authors: Cheolhee Won; Byung-Hak Kim; Eun Hee Yi; Kyung-Ju Choi; Eun-Kyung Kim; Jong-Min Jeong; Jae-Ho Lee; Ja-June Jang; Jung-Hwan Yoon; Won-Il Jeong; In-Chul Park; Tae Woo Kim; Sun Sik Bae; Valentina M Factor; Stephanie Ma; Snorri S Thorgeirsson; Yun-Han Lee; Sang-Kyu Ye
Journal: Hepatology Date: 2015-08-28 Impact factor: 17.425

8 in total

Review 1. Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance.

Authors: Masoud Najafi; Bagher Farhood; Keywan Mortezaee; Ebrahim Kharazinejad; Jamal Majidpoor; Reza Ahadi
Journal: J Cancer Res Clin Oncol Date: 2019-11-16 Impact factor: 4.553

2. Increased liver tumor formation in neutral sphingomyelinase-2-deficient mice.

Authors: Liansheng Zhong; Ji Na Kong; Michael B Dinkins; Silvia Leanhart; Zhihui Zhu; Stefka D Spassieva; Haiyan Qin; Hsuan-Pei Lin; Ahmed Elsherbini; Rebecca Wang; Xue Jiang; Mariana Nikolova-Karakashian; Guanghu Wang; Erhard Bieberich
Journal: J Lipid Res Date: 2018-03-22 Impact factor: 5.922

STAT3 is a key transcriptional regulator of cancer stem cell marker CD133 in HCC.

1. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity.

2. Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells.

3. A noncanonical Frizzled2 pathway regulates epithelial-mesenchymal transition and metastasis.

4. Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis.

5. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway.

Review 6. Cancer stem cells in the development of liver cancer.

Review 7. Cancer stem cells: impact, heterogeneity, and uncertainty.

8. Signal transducer and activator of transcription 3-mediated CD133 up-regulation contributes to promotion of hepatocellular carcinoma.

Review 1. Hypoxia in solid tumors: a key promoter of cancer stem cell (CSC) resistance.

2. Increased liver tumor formation in neutral sphingomyelinase-2-deficient mice.

3. Gene Expression Profiling of Hepatocellular Carcinoma Derived Cancer Stem Like Cell under Hypoxia.

4. EGFL6 promotes colorectal cancer cell growth and mobility and the anti-cancer property of anti-EGFL6 antibody.

Review 5. IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma.

6. Impact of Exogenous Treatment with Histidine on Hepatocellular Carcinoma Cells.

Review 7. Bladder cancer stem cells: clonal origin and therapeutic perspectives.

Review 8. Stem-Like Signature Predicting Disease Progression in Early Stage Bladder Cancer. The Role of E2F3 and SOX4.